Hergenhahn L, Padutsch N, Azawi S, Weiskirchen R, Liehr T, Rincic M
Cells. 2024; 13(22).
PMID: 39594637
PMC: 11593031.
DOI: 10.3390/cells13221889.
Miranda A, Pattnaik S, Hamilton P, Fuss M, Kalaria S, Laumont C
Sci Adv. 2024; 10(20):eadj5428.
PMID: 38748789
PMC: 11095474.
DOI: 10.1126/sciadv.adj5428.
Smith N, Reznik E, Bisikirska B, Polychronidou V, Wang Q, Zask A
ACS Med Chem Lett. 2023; 14(12):1664-1672.
PMID: 38116412
PMC: 10726605.
DOI: 10.1021/acsmedchemlett.3c00274.
Stokes M, Vasciaveo A, Small J, Zask A, Reznik E, Smith N
Cell Chem Biol. 2023; 31(4):805-819.e9.
PMID: 38061356
PMC: 11031350.
DOI: 10.1016/j.chembiol.2023.11.007.
Chaudhry K, Jacobi J, Gillard B, Karasik E, Martin J, da Silva Fernandes T
iScience. 2023; 26(11):108303.
PMID: 38026169
PMC: 10654598.
DOI: 10.1016/j.isci.2023.108303.
Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development.
Yuan Y, Alzrigat M, Rodriguez-Garcia A, Wang X, Sjoberg Bexelius T, Johnsen J
Cancers (Basel). 2023; 15(18).
PMID: 37760568
PMC: 10527308.
DOI: 10.3390/cancers15184599.
Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression.
Condurat A, Aminzadeh-Gohari S, Malnar M, Schider N, Opitz L, Thomas R
Sci Rep. 2023; 13(1):3760.
PMID: 36882436
PMC: 9992669.
DOI: 10.1038/s41598-023-29796-2.
Expression of ADRB2 in children with neuroblastoma and its influence on prognosis.
Cao L, Liu Q, Ma Y, Shao F, Zhao Z, Deng X
Front Surg. 2022; 9:1026156.
PMID: 36406346
PMC: 9666690.
DOI: 10.3389/fsurg.2022.1026156.
Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN.
Shi X, Wang Y, Zhang L, Zhao W, Dai X, Yang Y
Front Cell Dev Biol. 2022; 10:1021820.
PMID: 36187481
PMC: 9523081.
DOI: 10.3389/fcell.2022.1021820.
A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma.
Perri P, Ponzoni M, Corrias M, Ceccherini I, Candiani S, Bachetti T
Cancers (Basel). 2021; 13(21).
PMID: 34771690
PMC: 8582685.
DOI: 10.3390/cancers13215528.
MYCN Function in Neuroblastoma Development.
Otte J, Dyberg C, Pepich A, Johnsen J
Front Oncol. 2021; 10:624079.
PMID: 33585251
PMC: 7873735.
DOI: 10.3389/fonc.2020.624079.
Molecular switch from MYC to MYCN expression in MYC protein negative Burkitt lymphoma cases.
Mundo L, Ambrosio M, Raimondi F, Del Porro L, Guazzo R, Mancini V
Blood Cancer J. 2019; 9(12):91.
PMID: 31748534
PMC: 6868231.
DOI: 10.1038/s41408-019-0252-2.
The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35.
Liu P, Tee A, Milazzo G, Hannan K, Maag J, Mondal S
Nat Commun. 2019; 10(1):5026.
PMID: 31690716
PMC: 6831662.
DOI: 10.1038/s41467-019-12971-3.
Multiple direct interactions of TBP with the MYC oncoprotein.
Wei Y, Resetca D, Li Z, Johansson-Akhe I, Ahlner A, Helander S
Nat Struct Mol Biol. 2019; 26(11):1035-1043.
PMID: 31686052
DOI: 10.1038/s41594-019-0321-z.
MYCN gene polymorphisms and Wilms tumor susceptibility in Chinese children.
Huang X, Zhao J, Zhu J, Chen S, Fu W, Tian X
J Clin Lab Anal. 2019; 33(9):e22988.
PMID: 31343784
PMC: 7938399.
DOI: 10.1002/jcla.22988.
SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro.
Tummler C, Dumitriu G, Wickstrom M, Coopman P, Valkov A, Kogner P
Cancers (Basel). 2019; 11(2).
PMID: 30744170
PMC: 6406899.
DOI: 10.3390/cancers11020202.
Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R
Cancer Discov. 2018; 8(5):582-599.
PMID: 29510988
PMC: 5967627.
DOI: 10.1158/2159-8290.CD-16-0861.
Chronic radiation exposure of neuroblastoma cells reduces nMYC copy number.
Gnanamony M, Antony R, Fernandez K, Jaime L, Lin J, Joseph P
Oncol Lett. 2017; 14(3):3363-3370.
PMID: 28927089
PMC: 5587969.
DOI: 10.3892/ol.2017.6652.
EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markers.
Hansen J, Lotta Jr L, Eberhardt A, Schor N, Li X
J Cancer Res Ther (Manch). 2017; 4(2):11-18.
PMID: 28713571
PMC: 5507068.
DOI: 10.14312/2052-4994.2016-3.
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R
Oncoimmunology. 2017; 6(6):e1316439.
PMID: 28680748
PMC: 5486189.
DOI: 10.1080/2162402X.2017.1316439.